Zevra Denmark A/S
CVR 43259326 · Public limited company (A/S) · Active · Low risk
Zevra Denmark A/S is a Public limited company (A/S), founded on , based in Frederiksberg. The company is registered in the industry forskning og eksperimentel udvikling inden for naturvidenskab og teknik. Our model estimates a bankruptcy risk of 0.2% over the next 12 months, which is 0.2 times the average for Danish companies. 4 annual reports have been published, of which 4 more than six months after the end of the financial year. The latest annual report (31 Dec 2025) shows equity of DKK 174.8m and a net result of DKK 334.5m.
Bankruptcy risk for Zevra Denmark A/S
0.2 × the average (1.41%) · higher risk than 49% of active Danish companies
Increases the risk
Reduces the risk
The factors show how often companies with the same characteristic went bankrupt compared with the average (“lift”). The risk is a statistical estimate from a model trained on 141,000+ Danish bankruptcies (AUC 0.93) – not a credit rating. Read about the method.
Company details
- CVR number
- 43259326
- Status
- Active
- Company type
- Public limited company (A/S)
- Founded
- (4 years)
- Address
- Nordre Fasanvej 215
2000 Frederiksberg - Municipality
- Frederiksberg
- Industry
- Forskning og eksperimentel udvikling inden for naturvidenskab og teknik (721000)
Bankruptcies in the industry: Anden forskning og eksperimentel udvikling inden for naturvidenskab og teknik - Share capital
- DKK 400k
- Auditor
- EY Godkendt Revisionspartnerselskab
- Audit opted out
- No
Warning signs
| Annual reports filed late | 4 of 4 |
| Missing annual report | No |
| Negative equity | No |
| Equity ratio | 32.5% |
| Current ratio | 151% |
| Moves (last 2 years) | 0 |
| CEO changes in total | 0 |
| CEO's previous bankruptcies | 0 |
| Other companies at the address | 111 |
| Going-concern uncertainty | Yes |
Financials and key figures
| Financial year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Revenue | DKK 123.3m | DKK 71.0m | DKK 59.4m |
| Gross profit | DKK 404.0m | DKK -1.7m | DKK -12.5m |
| Net profit | DKK 334.5m | DKK -132.1m | DKK -20.5m |
| Equity | DKK 174.8m | DKK -159.6m | DKK -27.5m |
| Total assets | DKK 538.4m | DKK 178.2m | DKK 189.1m |
| Cash | DKK 19.8m | DKK 14.5m | – |
| Short-term debt | DKK 296.0m | DKK 275.0m | – |
| Tax owed | DKK 124.3m | DKK 98.3m | – |
| Avg. employees | 4 | 4 | – |
Latest annual report: Reporting class B · auditor's statement: Revisionspåtegning · EY Godkendt Revisionspartnerselskab.
Filed annual reports
| Reporting period | Published | Days after period end | |
|---|---|---|---|
| 1 Jan 2025 – 31 Dec 2025 | 189 | Late | |
| 1 Jan 2024 – 31 Dec 2024 | 199 | Late | |
| 1 Jan 2023 – 31 Dec 2023 | 199 | Late | |
| 13 May 2022 – 31 Dec 2022 | 205 | Late |
The annual report must reach the Danish Business Authority no later than 5 months after the end of the financial year. We mark reports published more than 6 months after as “late”.
Management, owners and auditor
| Role | Name | From | To |
|---|---|---|---|
| Board | Thomas Weitemeyer | Current | |
| Board | Rahsaan Waleed Thompson | Current | |
| Board | Timothy Sangiovanni | Current | |
| Board | Justin Andrew Renz | Current | |
| Board | Raymond La Duane Clifton | ||
| Board | Travis Clark Mickle | ||
| Board | Neil McFarlane | ||
| Owner (100%) | Zevra Therapeutics, Inc. | Current | |
| Auditor | EY Godkendt Revisionspartnerselskab | Current | |
| Auditor | RSM DANMARK STATSAUTORISERET REVISIONSPARTNERSELSKAB | ||
| Founder | Zevra Therapeutics, Inc. | Current |
Address history (2 moves)
| Nordre Fasanvej 215, 2000 Frederiksberg | |
| Ole Maaløes Vej 3, 2200 København N | |
| c/o Moalem Weitemeyer, Amaliegade 3, 1256 København K |
Former names
| Zevra Denmark A/S | – now |
| KemPharm Denmark A/S | – |
Other companies at the same address
- Nordetect ApS Bankrupt
- ACESION PHARMA ApS Active
- AdaptVac ApS Active
- Adcendo ApS Active
- Akylox Therapeutics ApS Active
- Antraka ApS Opløst
- Augustine Therapeutics Denmark ApS Active
- Autocert ApS Active
- Avancert ApS Active
- B4C ApS Active
- BOOST Pharma ApS Active
- Baekmark IP Consult ApS Active
- Betula Capital ApS Active
- BioPhenyx ApS Active
- Biobridge Partners ApS Active
- Biotinia ApS Active
- CMCAssist ApS Active
- CMCGreenhouse ApS Active
- CMCHoldings ApS Active
- CaMaRa ApS Active
- Catalyst Vaccination A/S Active
- Chris Cording Jønsson Holding ApS Active
- DARERL ApS Active
- DFY ApS Active
- DeltaBot ApS Active
Similar companies in Frederiksberg
- Catalyst Vaccination A/S Frederiksberg
- RefuelBio ApS Frederiksberg
- BioMomentum Advisors ApS Frederiksberg
- Oak Mountain Consulting ApS Frederiksberg
- Biotinia ApS Frederiksberg
- Nordic BioVentures ApS Frederiksberg C
- BioPhenyx ApS Frederiksberg
- BioSpringbok ApS Frederiksberg
- Orbis Medicines ApS Frederiksberg
- Epoqe Pharma ApS Frederiksberg
- SJM IP ApS Frederiksberg C
- Pephexia Therapeutics ApS Frederiksberg
Questions and answers about Zevra Denmark A/S
Has Zevra Denmark A/S gone bankrupt?
No, Zevra Denmark A/S is not registered as bankrupt in the CVR register. Its status is: active.
What is the bankruptcy risk of Zevra Denmark A/S?
Our model estimates a bankruptcy risk of 0.2% over the next 12 months (low risk), which is 0.2 times the average for Danish companies.
Who is the auditor of Zevra Denmark A/S?
Zevra Denmark A/S most recently used EY Godkendt Revisionspartnerselskab.
When was Zevra Denmark A/S founded?
Zevra Denmark A/S was founded on 13 May 2022.
What is the equity of Zevra Denmark A/S?
Equity was DKK 174.8m according to the annual report for the period ending 31 December 2025.
Source: the CVR register and annual reports published by the Danish Business Authority. The information is updated continuously.